Chordia Therapeutics
IPODeveloping next-generation small-molecule anticancer drugs
Chordia Therapeutics was founded in 2017, is headquartered in Fujisawa, Japan, and has $69.0M in recorded funding across 3 rounds.
- Headquarters
- Fujisawa
- Founded
- 2017
- Business Model
- B2B
- Website
- chordiatherapeutics.com
- Total Funding
- $69.0M
- Last Round
- $31.0M Series CMay 2022
- Rounds
- 3
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 5 investors for this company. The full record is or through the API.
About
Chordia Therapeutics is a Japanese clinical-stage biotech company headquartered in Fujisawa, Kanagawa, founded in October 2017 and publicly listed on the Tokyo Stock Exchange (ticker: 190A). The company is engaged in the research and development of next-generation small-molecule anticancer drugs with novel mechanisms of action, focusing on RNA splicing dysregulation and inducing stress overload in cancer cells — a newly proposed hallmark of cancer. Its lead program, Rogocekib (a CLK inhibitor), has advanced into Phase 1 clinical trials for solid tumors, and the company also partners with Takeda and leading academic institutions including Kyoto University and Fujitsu to discover biomarkers and advance its pipeline. Chordia targets cancers with high unmet medical needs using a precision oncology approach grounded in solid scientific evidence.
Summary
Chordia Therapeutics is an Oncology company based in Fujisawa, Japan, founded in 2017. It has raised $69.0M in total across 3 rounds, most recently a $31.0M Series C round in May 2022. Investors include Jafco Ventures, Kyoto University Innovation Capital and SMBC Venture Capital.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Jun 2024
Sign up to see all 4 events
Funding: Series A through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/chordia-therapeutics"><img src="https://indexed.vc/api/badge/company/chordia-therapeutics" alt="Chordia Therapeutics on Indexed.vc" width="260" height="76" /></a>